Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?

Vaccine

Volumn 30, Issue 17, 2012, Pages 2795-2800

  Bilcke, Joke ^a   Ogunjimi, Benson ^a   Hulstaert, Frank ^b   Van Damme, Pierre ^a   Hens, Niel ^a,c   Beutels, Philippe ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

Author keywords

Model uncertainty; Shingles; Waning; Zoster

Indexed keywords

PLACEBO; VARICELLA ZOSTER VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FOLLOW UP; HERPES ZOSTER; MODEL; PRIORITY JOURNAL; TIME; VACCINATION;

AGE FACTORS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MODELS, STATISTICAL; TIME FACTORS;

EID: 84355162354     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.079     Document Type: Article

References (29)

1. Choo P.W., Donahue J.G., Manson J.E., Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995, 172(3):706-712.
2. Gershon A., Takahashi M., Seward J. Varicella vaccine. Vaccines 2008, 915-958. Saunders, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
3. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
4. Thomas S.L., Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4(1):26-33.
5. Drolet M., Brisson M., Levin M.J., Schmader K.E., Oxman M.N., Johnson R.W., et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010, 26(8):656-666.
6. Helgason S., Petursson G., Gudmundsson S., Sigurdsson J.A. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000, 321(7264):794-796.
7. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-2284.
8. Annemans L., Bresse X., Gobbo C., Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ 2010, 13(3):537-551.
9. Brisson M., Pellissier J.M., Camden S., Quach C., De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Human Vaccines 2008, 4(3):238-245.
10. Edmunds W.J., Brisson M., Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19(23-24):3076-3090.
11. Hornberger J., Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006, 145(5):317-325.
12. Najafzadeh M., Marra C.A., Galanis E., Patrick D.M. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009, 27(12):991-1004.
13. Pellissier J.M., Brisson M., Levin M.J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007, 25(49):8326-8337.
14. Rothberg M.B., Virapongse A., Smith K.J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007, 44(10):1280-1288.
15. van Hoek A.J., Gay N., Melegaro A., Opstelten W., Edmunds W.J. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009, 27(9):1454-1467.
16. van Lier A., van Hoek A.J., Opstelten W., Boot H.J., de Melker H.E. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res 2010, 10:237.
17. Bilcke J, Marais C, Ogunjimi B, van Hoek AJ, Lejeune O, Callens M, et al. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. KCE reports 151; 2011. http://www.kce.fgov.be/index_en.aspx%3FSGREF=5211%26CREF=18897.
18. Merck. Zoster vaccine live (Oka/Merck) Zostavax. FDA clinical briefing document for Merck and Co.; 2005. Available from: [accessed 13.09.11]. http://www.fda.gov/ohrms/dockets/ac/05/briefing/5-4198B2_1.pdf.
19. Schmader K., Oxman M., Levin M., Betts R.F., Morrison V.A., Gelb L.D., et al. Persistence of zoster vaccine efficacy 2008, ICAAC/IDSA, Durham.
20. Hurvich C.M., Tsai C.L. Regression and time-series model selection in small samples. Biometrika 1989, 76(2):297-307.
21. Ahnn S. FDA statistical review and evaluation: zostavax. Document for the Vaccines and Related Biological Products Advisory Committee 2005.
22. Levin M.J., Oxman M.N., Zhang J.H., Johnson G.R., Stanley H., Hayward A.R., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008, 197(6):825-835.
23. Levin M.J., Smith J.G., Kaufhold R.M., Barber D., Hayward A.R., Chan C.Y., et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003, 188(9):1336-1344.
24. Jackson C.H., Bojke L., Thompson S.G., Claxton K., Sharples L.D. A framework for addressing structural uncertainty in decision models. Med Decis Making 2011, 31(4):662-674.
25. Bilcke J., Beutels P., Brisson M., Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011, 31(4):675-692.
26. Durham L.K., Halloran M.E., Longini I.M., Manatunga A.K. Comparison of two smoothing methods for exploring waning vaccine effects. J R Stat Soc C - Appl 1999, 48:395-407.
27. Durham L.K., Longini I.M., Halloran M.E., Clemens J.D., Nizam A., Rao M. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Am J Epidemiol 1998, 147(10):948-959.
28. Coplan P.M., Schmader K., Nikas A., Chan I.S., Choo P., Levin M.J., et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004, 5(6):344-356.
29. Chang M.N., Guess H.A., Heyse J.F. Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med 1994, 13(18):1807-1814.